

Eliza Tsitoura PhD.
Laboratory of Molecular and Cellular Pneumonology,
School of Medicine, University of Crete, Heraklion, Greece.
e.tsitoura@uoc.gr +30 2810 394 668/ +30 6979 543 823
<https://orcid.org/0000-0001-9356-171X>

Date and place of birth 11/12/1972, Athens, Greece
Languages Greek , English , French

Summary

- Associate researcher at the Laboratory of Molecular and Cellular Pulmonology, School of Medicine, University of Crete (UOC) since 2014, with 45 peer reviewed publications, h index-17 and 861 citations to date (source: Scopus). Holds a 1st class honours degree in Medical Microbiology from University College London (1995) and a PhD in Biological Chemistry from the National and Kapodistrian University of Athens (2003).
- Studied the envelope glycoproteins of the hepatitis C virus and developed a virus-like particle (VLP) platform for HCV at the Molecular Virology Laboratory of the Hellenic Pasteur Institute in Athens. Following her PhD, she conducted postdoctoral research at Claude Bernard-Lyon 1 University in Lyon, France, and later at the Hellenic Pasteur Institute in Athens on the effect of virus-based vaccine vectors and VLPs on splenic dendritic cells.
- Her research interest has focused for the last ten years on airway macrophages in Idiopathic Pulmonary Fibrosis and Diffuse Interstitial Lung Diseases associated with autoimmune pathologies, including post-COVID-19 ILD. For her work, she has received funding from the Hellenic Thoracic Society and from major pharmaceutical companies such as Boehringer Ingelheim, for the discovery of new biomarkers necessary for the accurate diagnosis and prognosis of patients with interstitial lung diseases.
- Currently, she is co-coordinating an in-depth biomarker discovery clinical study in Interstitial Lung Diseases, analysing patients' samples with scRNA seq, bulk transcriptomics, breath metabolomics and flow cytometry in a cohort of 150 patients at the Laboratory of Molecular and Cellular pulmonology, UOC Medical School.

Scientific Expertise -Technical Proficiency-Professional skills

Cellular and In Vitro Models: Expertise in Human Lung Primary cell isolation, Biobanking, and maintaining Tissue culture. Proficient in a range of cell based assays including Proliferation, Migration, Apoptosis, and Toxicity, alongside specialized Extracellular Flux analysis (Seahorse Analyser) for metabolic functional assays. **Molecular & 'Omics' Technologies:** Skilled in high-throughput analysis, including Single-cell RNA sequencing and NGS (Next-Generation Sequencing). Competent in routine molecular techniques such as qPCR, RT-PCR, Western blot, and ELISA for quantifying gene and protein expression. **Advanced Imaging & Cytometry:** Experienced in cell sorting and detailed phenotyping using Flow cytometry, advanced microscopy and immunodetection methods, including Confocal Microscopy, IF (Immunofluorescence), and IHC (Immunohistochemistry). **Data Analysis & Software:** Proficient with industry-standard analysis tools: ImageJ, FlowJo, GraphPad Prism, and GSEA (Gene Set Enrichment Analysis), complemented by general productivity with Microsoft office. **Project Leadership:** Proven ability in Protocol development, Laboratory and Project management, Mentorship, and Supervision. Effective in communication and fostering Cross-functional team collaboration.

Education

1992-1995	B.Sc. in Medical Microbiology, First class, Honours degree University College of London, Biology Department, London, UK.
1997-2003	PhD. in Biological Chemistry, degree "excellent"

“Study of the envelope glycoproteins of Hepatitis C Virus using Herpes Simplex 1 virus (HSV-1) based expression vectors.” <https://www.didaktorika.gr/eadd/handle/10442/19859>

Medical School, Kapodistrian University of Athens, Department of Biological Chemistry, Athens, Greece and Laboratory of Molecular Virology, Hellenic Pasteur Institute, Athens, Greece.

Work experience-Research positions

- 2014 to date** **Senior research scientist** at the Laboratory of Cellular and Molecular Pulmonology, Department of Respiratory Medicine, Medical School, University of Crete, Heraklion, Crete, Greece (PI Prof. K.M Antoniou)
- 2012- 2014** **Post-Doctoral fellow of TransPOT FP7/EU**, at the Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Crete, Greece (PI Prof. Dr. G. Sourvinos)
- 2007-2012** **Post-doctoral fellow of CompuVac FP6/EU**, at the Molecular Virology Laboratory, Hellenic Pasteur Institute, Athens, Greece. (PI Dr. P. Mavromara)
- 2003-2006** **Post-doctoral fellow with AFM scholarship**, at the Laboratory of Molecular Genetics of herpes simplex virus type 1 (HSV-1), Université Claude Bernard-Lyon I, Lyon, France. (CompuVac FP6/EU Grant and AFM scholarship) (PI Prof Dr. AL. Epstein)
- 1997-2002** **PhD student**, at the Molecular virology Laboratory, Hellenic Pasteur Institute (PI Dr. P. Mavromara) and Kapodistrian University of Athens, Medical School, Department of Biological Chemistry, Athens, Greece (Prof K. Trogkos)
- 1996-1997** **Post-Graduate student**, at the Department of Hematological Medicine, University of Cambridge Clinical School, Cambridge, U.K. (Prof. A. Karpas)
- 1995-1996** **Undergraduate research training**, at the Virology Department, UCH (University College Hospital) Middlesex Hospital, London, UK (Dr. P. Balfe)

Scholarships and awards

- 2025** 1st Award for oral presentation, 34th annual conference of the Hellenic Thoracic Society, December 2025: “Single-cell analysis identifies rare CCL^{hi} monocyte-derived alveolar macrophages as a potential ILD biomarker” **E. Tsitoura**, J. Spingte, E. Vasarmidi, T. Beckmann, B. Reiz, H. Dickten, T. Ulas, I. Argyriou, M. Lourou, J. Soeliner, L. Wollin, C. Hesslinger, C.T. Wohnhaas, P. Baum, K.M Antoniou.
- 2017** 1st Award for oral presentation, 26th annual conference of the Hellenic Thoracic Society, November 2017 : “IPF BALF Cells Show Reduced Expression of PINK1 Coupled to Elevated Oxidized Mitochondria Levels.” E. Vasarmidi, **E. Tsitoura**, C. Koutoulaki, G. Margaritopoulos,, N. Tzanakis, K.M. Antoniou.
- 2016** 3rd Award for oral presentation, 25th annual conference of the Hellenic Thoracic Society, June 2016 “MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF alveolar macrophages. Vasarmidi E., **Tsitoura E**, Wells AU, Karagiannis K, Lasithiotaki I, Bibaki E, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM.
- 2015** 1st Award for oral presentation at the 24th annual conference of Hellenic Thoracic Society, November 2015 “Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages- a mitophagy study in bronchoalveolar lavage fluid.” E. Vasarmidi, **E. Tsitoura**, S. Michelakis, C. Koutoulaki, G. Margaritopoulos, I. Charalampous, E. Lampiri, N. Tzanakis, D. Georgopoulos, KM. Antoniou.
- 1st Award for - e-poster presentation at the 24th annual conference of Hellenic Thoracic Society, November 2015 “Expression of miR-185 targets, DNA methyltransferase 1 and Cyclin D2 in IPF and lung cancer in

2003-2004 “Aide aux etudes”, Groupe E, dossier n°9742, Association Française contre les Myopathies (AFM)

2002-2003 “Aide aux etudes”, Groupe 3, dossier n°8887, Association Française contre les Myopathies (AFM)

Research Grants-Funding

Author

- Recipient of **Hellenic Thoracic Society Research Grant** for 2025: “The Role of T Cell Telomere Attrition in Immune Dysregulation and Disease Progression in Pulmonary Fibrosis.” (15,000 euros).
- Recipient of **Hellenic Thoracic Society Research Grant** for 2018 “Identification of putative common and distinct phenotypic and metabolic states of Alveolar Macrophage sub-populations in Idiopathic Pulmonary Fibrosis (IPF) and non-IPF fibrotic ILDs.”(15,000 euros).
- Recipient of **Hellenic Thoracic Society Research Grant** for 2016 “Development of ‘anti-fibrotic/fibrolytic’ HSV-1 recombinant vectors targeting IL-13 responsive cells to combat pulmonary fibrosis.” (15,000 euros).

Principal Co-Author

- **SUB1.1. Ministry of Education-Epiteliki drasi-2024** “FIBRO-BREATH-Integration of Volatile Organic Compounds (VOCs) in the Diagnosis of Fibrotic Interstitial Lung Diseases”. Project Approved-Funding decision pending (400,000 euro)
- **Hellenic Thoracic Society, Research Award** for 2022 for the project entitled, “The role of the anti-aging protein, a-Klotho, on metabolism and mitochondrial homeostasis of monocytes/macrophages in IPF patients and patients with progressive pulmonary fibrosis (PPF).” (15,000 euro)
- **Hellenic Thoracic Society, Research Award** for 2021 for the project entitled, “The effect of SGLT2 inhibitors on metabolism, mitochondrial homeostasis of monocytes/macrophages and progression of fibrosis in IPF and CTD-ILD patients.” (15,000 euro)
- **Hellenic Foundation for Research and Innovation HFRI** grant for Faculty members (2020), “HFRI-FM17-2143, Metabolic FibroClock” (180,000 euro).
- **Research Grant supported by Boehringer Ingelheim** (2020), “An interventional study without an investigational medicinal product to differentially diagnose patients with interstitial lung diseases (ILDs), to monitor disease progression, and to identify molecular markers. (570,000 euro)
- **Hellenic Thoracic Society, Research Award** for 2015 for the project entitled, ‘Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages - a mitophagy study in bronchoalveolar lavage fluid (BALF)’ (15,000 euro)
- **Hellenic Thoracic Society, Research Award** for 2013 for the project entitled, “Regulation of autophagy in IPF bronchoalveolar lavage fluid (BALF)” (15,000 euro)

Courses and Training workshops

- **Digital PCR-Applications and analysis. (2017)**

TATAA Biocenter in conjunction with the 21st World Congress on advances in Oncology and 19th International Symposium on Molecular Medicine.

- **State-of-the-art genome editing technology (CRISPR/Cas9) and establishment of research collaboration on genome engineering approaches. (2017).**
Ioannis Sanidas, PhD, Massachusetts General Hospital Center for Cancer Research, Harvard Medical School, Greek Diaspora Fellowship Program, Medical School, University of Crete.
 - **2nd HKU-Pasteur Immunology course (2009)**
Hong Kong University Pasteur Research centre. Organisers R. Bruzzone, HKU-PRC, J-M. Cavaillon, Institute Pasteur, Paris and A. Lau, University of Hong Kong.
 - **Intensive training session on the CodeLink Microarray platform. (2008)**
European Molecular Biology Laboratory (EMBL) Genomics Core facility. Heidelberg, Germany. V. Benes, (EMBL).
 - **1st Bioinformatics and comparative genome analysis course (2006)**
Pasteur Institute Pasteur of Tunis. Organisers F. Tekai, Institute Pasteur, Paris and A. Benkahla, Institute Pasteur, Tunis.
-

Teaching experience

Lectures in Undergraduate and post-Graduated courses

1. **"Fibrogenesis and Fibro-metabolism"**
Pathophysiology A, 5th semester, International program in medicine, University of Crete, Medical school (October 2025)
2. **"Molecular and cellular pneumonology Laboratory"**
Pathophysiology A, 5th semester, International program in medicine, University of Crete, Medical school (October 2025)
3. **"Acute infection and long-term sequelae of SARS-Cov-2 infection"**
1st Tinos Immunovirology Masterclass, EMORY University, Democritus University of Thrace and The University of Western Australia (September 2025)
4. **"Detection methods of SARS-CoV-2 infection"**
COVID-19 Courses of the Thoracic Medicine Department, University Hospital of Heraklion, Medical School, University of Crete, Heraklion. 2019-2020,
5. **"Herpesviruses"**
Interdepartmental MSc degree in Infectious Diseases and International Medicine "From Bench to Bedside"
School of Health Sciences, Department of Medicine, Department of Molecular Biology and Genetics, Democritus University of Thrace. (January 2020).
6. **"Virotherapy-the turning of "killers" into cures"**
Interdepartmental MSc degree in Infectious Diseases and International Medicine "From Bench to Bedside"
School of Health Sciences, Department of Medicine, Department of Molecular Biology and Genetics, Democritus University of Thrace. (December 2017).
7. **"Pathogenesis of IPF".**
Post Graduate course in ILDs: From bench to bedside Thoracic Medicine Department, University of Crete, Heraklion, Greece, (May 2017)

Invited Lectures

1. **"What we have learned from single cell data in fibrotic lung diseases"**
5th SHARE pre-conference-2nd ILD Greek Turkish Workshop (July 2025)

2. **“Unveiling the Immune response behind Long-Term lung complications in COVID-19 survivors”**
4th SHARE congress (June 2024)
3. **“Breath analysis in ILDs”**
3rd SHARE congress (June 2023)
4. **“ Circadian Rhythm and pulmonary fibrosis: novel insights”**
3rd SHARE congress (June 2023)
5. **“BALF procedure and Flow Cytometry in the Laboratory of Molecular & Cellular Pneumology”**
2nd SHARE-Cretan Summer School of respiratory Department, Interstitial Lung Diseases Course: from bench to bedside. University of Crete, Heraklion, Greece, (June 2022)
6. **“Novel methodology of Breath Analysis”**
2nd SHARE-Cretan Summer School of respiratory Department, Interstitial Lung Diseases Course: from bench to bedside. University of Crete, Heraklion, Greece, (June 2022)
7. **“Virus-based vaccine delivery vectors for dendritic cell activation”**
4th Congress of Gene Therapy and Regenerative medicine, Hellenic society of gene therapy and regenerative medicine. (May 2019)
8. **“Recent advances highlighting the pro-fibrotic role of Alveolar Macrophages in Pulmonary Fibrosis”**
3rd Workshop of postgraduate and postdoctoral researchers, Hellenic Pasteur Institute, Athens, European Researchers Night 2017. (September 2017)
9. **“Epigenetics in IPF”**
1st SHARE-ILD, Cretan Summer School of respiratory Department, Interstitial Lung Diseases Course: from bench to bedside. University of Crete, Heraklion, Greece, (July 2017)
10. **“Dendritic cell signatures of virus-based vaccine delivery vehicles”.**
5th annual DC-THERA network meeting, Athens. (May 2010).
11. **“Molecular signatures of vaccine vectors”.**
Theoretical Course of the FP6 framework program HEVAR (HErpesvirus-based VAccines for the Rotavirus infection), Institute Pasteur of Montevideo, Uruguay. (April 2008).
12. **“Herpes simplex virus type 1 (HSV-1)-based amplicon vectors expressing the structural region of the hepatitis C virus (HCV)”.**
Institute de Génétique Moléculaire, CNRS UMR 5535, Montpellier, France. (April 2003).

Co-Supervision of Graduate and Post graduate students-projects

PhD students

1. Olga Bourogianni, student of the PhD program of the Department of Nuclear Medicine, Medical School, University of Crete, **“Disease relevant preoperative Serum miRNA levels in Papillary Thyroid Cancer”**. (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2022-2026)
2. Styliani Sarantoulaki, student of the PhD program of the Thoracic Department, Medical School University of Crete, **“Study of autophagy and NLRP3 inflammasome activation in Bronchoalveolar Lavage cells from IPF and RA-ILD patients”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2017-2021)
3. Sperelakis Ioannis, student of the PhD program of the Orthopedics Department, Medical School, University of Crete **“Influence of reaming intramedullary nailing on MSC population after surgical treatment of patients with long bone fracture”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2017-to 2020).

4. Athina Trachalaki, student of the PhD program of the Thoracic Medicine Department, Medical School, University of Crete **“Inflammasome activation in fibrotic ILDs in airway macrophages** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2017-to 2020).
5. Eirini Vasarmidi, student of the PhD program of the Thoracic Department, Medical School University of Crete **“Autophagy and mitophagy status in IPF – a study in bronchoalveolar lavage fluid cells.”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2016-2019).
6. Eleni Bibaki, student of the PhD program of the Thoracic Department, Medical School University of Crete. **“IPF and Lung cancer common pathogenetic pathways in BAL cells”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete 2014-2018).
7. Manolis Kochlios, student of the PhD program of the Medical School of the Kapodistrian University of Athens, Department of Biological Chemistry, Athens, Greece, in **“Investigation of the signaling pathways affected by HCV core protein leading to immunomodulatory functions”**. (Laboratory of molecular virology, Hellenic Pasteur Institute 2009-2010).

MSc Students

1. Dimitra-Maria Zevla, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, Master thesis title: **“The role of RORa in human lung fibroblasts in IPF”**(Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2021-2022)
2. Konstantina Pampouka, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, 3 months rotation, **“Analysis of Bronchoalveolar Lavage cells”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2022)
3. Asimina Kakale, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, 3 months rotation, **“The role of RAR-Related Orphan Receptor A (RORa) in fibroblast migration”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2022)
4. Katerina Karagianni, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, 3 months rotation, “ Expression of **RAR-Related Orphan Receptor A (RORa) in human lung fibroblast culture from IPF patients”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2017)
5. Eirini Vasarmidi, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, thesis title **“Autophagy and mitophagy status in IPF – a study in bronchoalveolar lavage fluid cells.”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2015).
6. Chrysanthi Moschandrea, student of the MSc program “Molecular Basis of Human Diseases” of the Medical School of the University of Crete, 3 months rotation, **“microRNA -185 induced downregulation of AKT1 expression in ThP1 cells”** (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2015)
7. Emmanuel De Castro, Master 2 (M2) student, of the course of “Cellular and molecular Infectiology and vaccinology”, Université François-Rabelais de Tours, Tours, France. **“ Development and use of mammalian cell adapted baculovirus (BacMam) expression system for the functional analysis of HCV proteins”**. (Laboratory of molecular virology, Hellenic Pasteur Institute, 2010).
8. Yoran Margaron, Master 1 (M1) student, in the course of “Functional genetics and oncology”, Université Claude Bernard-Lyon I, Lyon. France. **“Study of the antiviral responses induced by HSV-1 amplicon vectors expressing the ICP0 immediately early protein”** (Laboratory of Molecular Genetics of herpes simplex virus type 1 (HSV-1), 2005)
9. Mathieu Mateo, Master 1 (M1) student, in the course of “Cellular and Molecular Biology, Oncologie”, Ecole Normale Supérieure de Lyon/Université Claude Bernard-Lyon I, Lyon. France. **“HSV-1 amplicon expression is cell type dependent and induce a cellular antiviral response in primary cells.”** (Laboratory of Molecular Genetics of herpes simplex virus type 1 (HSV-1), 2005).

Undergraduate Students

1. Stavroula Varda, student of the Medical School, of the University of Crete, Course: "Basic research in Medicine", thesis title, "**Investigation of molecular markers in patients with IPF-OSA overlap syndrome**" (Laboratory of molecular and cellular pneumonology, Medical School University of Crete, 2016)
2. Grégory Berger, 2nd year undergraduate student, of the Institut Universitaire de Technologie, Université Claude Bernard-Lyon I, Lyon. France. "**Study of the role of the ICP0 immediately early protein present in the tegument of HSV-1 based amplicon vectors**". (Laboratory of Molecular Genetics of herpes simplex virus type 1 (HSV-1). 2005)

Publications

Total publications : 45 peer reviewed publications,

1st/2nd author : 24

Last author :1

h-index : 16/ **Citations**: 1,129 (source: ResearchGate) (researchgate.net/profile/Eliza-Tsitoura)

h-index : 17 / **Citations** : 866 (source: Scopus) ([Scopus Author ID: 6506431347](https://scopus.com/authid/detail/authid/6506431347))

h-index : 19 / **Citations** : 1,421 (source: Google Scholar) ([Eliza Tsitoura-Google Scholar](https://scholar.google.com/citations?user=Eliza-Tsitoura))

Original research –peer reviewed publications

1. Bourogianni M.B, **Tsitoura E.**, Sifakis K., Kapsoritakis K., Karatzanis A., Doulaptsi M., Antoniou K.M., Koukouraki S., Prokopakis E. *Disease relevant preoperative Serum miRNA levels in Papillary Thyroid Cancer.* **Biology (Basel).** 2026 Apr 16;15(8):626.
2. Antoniou K.M *, Vasarmidi E. *, Galaras A., Lourou M., Argyriou I., Zevla D.M., Bizymi N., Skiadas C., Lambiri I., Hatzis P., Aidinis V, Tzanakis N., Wells A.U., **Tsitoura E.**
BALF gene expression profiling reveals a fibrosis associated innate immune activation bias in persistent post-COVID-19 ILD. **Am J Physiol Lung Cell Mol Physiol.** 2026 Jan 1;330(1):L33-L48
3. Chatziantoniou A, Karagiannis K, Mathioudakis AG, **Tsitoura E**, Synolaki E, Apostolou E, Sideras P, Tzanakis N, Siafakas NM, Antoniou KM.
Activin A/Follistatin Axis in Airway Diseases and its Association With Recurrent Exacerbations. **In Vivo.** 2025 Sep-Oct;39(5):2573-2583.
4. Bouloukaki I, Michelakis S, **Tsitoura E**, Vasarmidi E, Koutoulaki C, Tzanakis N, Schiza S, Antoniou KM.
KL-6, ET-1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea. **Exp Ther Med.** 2024 Nov 18;29(1):16.
5. Galaris A, Fanidis D, **Tsitoura E**, Kanellopoulou P, Barbayianni I, Ntatsoulis K, Touloumi K, Gramenoudi S, Karampitsakos T, Tzouveleakis A, Antoniou K, Aidinis V.
Increased lipocalin-2 expression in pulmonary inflammation and fibrosis. **Front Med (Lausanne).** 2023 Sep 7;10:1195501.
6. Barbayianni I, Kanellopoulou P, Fanidis D, Nastos D, Ntouskou ED, Galaris A, Harokopos V, Hatzis P, **Tsitoura E**, Homer R, Kaminski N, Antoniou KM, Crestani B, Tzouveleakis A, Aidinis V.
SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis. **Nat Commun.** 2023 Sep 21;14(1):5882.
7. **Tsitoura E**, Trachalaki A, Vasarmidi E, Mastrodemou S, Margaritopoulos GA, Kokosi M, Fanidis D, Galaris A, Aidinis V, Renzoni E, Tzanakis N, Wells AU, Antoniou KM.
Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality **Front Immunol.** 2021 Nov 17;12:645548.
8. Kachris S, Papadaki C, Rounis K, **Tsitoura E**, Kokkinaki C, Nikolaou C, Sourvinos G, Mavroudis D.
Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. **Cancer Manag. Res.** 2021 Nov 2;13:8257-8271

9. Trachalaki A, **Tsitoura E**, Mastrodinou S, Invernizzi R, Vasarmidi E, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, Antoniou K.
Enhanced IL-1 β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. **Front Immunol.** **2021** Jun 15;12:661811
10. Sperelakis I, **Tsitoura E**, Koutoulaki C, Mastrodinou S, Tosounidis TH, Spandidos DA, Antoniou KM, Kontakis G.
Influence of reaming intramedullary nailing on MSC population after surgical treatment of patients with long bone fracture. **Mol Med Rep.** **2020**;22(3):2521-2527.
11. **Tsitoura E**, Vasarmidi E, Bibaki E, Trachalaki A, Koutoulaki C, Papastratigakis G, Papadogiorgaki S, Chalepakis G, Tzanakis N, Antoniou KM.
Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. **Respir Res.** **2019**;20(1):264.
12. Lasithiotaki I, **Tsitoura E**, Samara KD, Trachalaki A, Charalambous I, Tzanakis N, Antoniou K.M.
NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. **PLoS One.** **2018** Oct 26;13(10):e0205242.
13. **Tsitoura E**, Kazazi D, Öz-Arslan D, Sever EA, Khalili S, Vassilaki N, Aslanoglou E, Dérian N, Six A, Sezerman OU, Klatzmann D, Mavromara P.
Comparison of DCs activation by virus-based vaccine delivery vectors emphasises the transcriptional downregulation of the oxidative phosphorylation pathway. **Hum Gene Ther.** **2018** Oct 23. doi: 10.1089/hum.2018.161.
14. Bibaki E, **Tsitoura E**, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Spandidos DA, Tzanakis N, Antoniou KM.
MiR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns. **Mol Med Rep.** **2018** May;17(5):7105-7112.
15. Samara KD, Trachalaki A, **Tsitoura E**, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, Antoniou KM.
Upregulation of citrullination pathway: From Rheumatoid associated to Idiopathic Pulmonary Fibrosis. **Respir Res.** **2017** Dec 29;18(1):218.
16. Karagiannis K, Proklou A, **Tsitoura E**, Lasithiotaki I, Kalpadaki C, Moraitaki D, Sperelakis I, Kontakis G, Antoniou KM, Tzanakis N.
Impaired mRNA Expression of the Migration Related Chemokine Receptor CXCR4 in Mesenchymal Stem Cells of COPD Patients. **Int J Inflam** **2017**, 2017:6089425.
17. **Tsitoura E**, Wells AU, Karagiannis K, Lasithiotaki I, Vasarmidi E, Bibaki E, Koutoulaki C, Sato H, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM.
MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells. **Oncotarget.** **2016**;7(46):74569-81.
18. Lasithiotaki I, **Tsitoura E**, Koutsopoulos A, Lagoudaki E, Koutoulaki C, Pitsidianakis G, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM.
Aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer. **Oncotarget.** **2016**.
19. Lasithiotaki I, Giannarakis I, **Tsitoura E**, Samara KD, Margaritopoulos GA, Choulaki C, Vasarmidi E, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, Antoniou KM.
NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. **Eur Respir J.** **2016**;47(3):910-8.
20. Dérian N, Bellier B, Pham HP, **Tsitoura E**, Kazazi D, Huret C, Mavromara P, Klatzmann D, Six A.
Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses. **PLoS Comput Biol.** **2016**;12(3):e1004801.
21. Oz-Arslan D*, **Tsitoura E***, Kazazi D, Kouvatsis V, Epstein AL, Mavromara P. (* equal contribution)
Murine Bone Marrow-Derived Dendritic Cells Transduced by Light-Helper-Dependent Herpes Simplex Virus-1 Amplicon Vector Acquire a Mature Dendritic Cell Phenotype. **Hum Gene Ther. Methods.** **2015**;26(3):93-102.

22. Karamichali E, Foka P, **Tsitoura E**, Kalliampakou K, Kazazi D, Karayiannis P, et al. *HCV NS5A co-operates with PKR in modulating HCV IRES-dependent translation. **Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases.** 2014;26:113-22.*
23. Nikitas N, Karadimou A, **Tsitoura E**, Soupos N, Tsiatas M, Karavasilis V, et al. *Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. **Pharmacogenomics.** 2012;13(14):1595-607.*
24. **Tsitoura E**, Thomas J, Cuchet D, Thoinet K, Mavromara P, Epstein AL. *Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. **The Journal of general virology.** 2009;90(Pt 9):2209-20.*
25. Kouvatsis V, Argnani R, **Tsitoura E**, Arsenakis M, Georgopoulou U, Mavromara P, Manservigi R. *Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins. **Virus research.** 2007;123(1):40-9.*
26. Lucas M, **Tsitoura E**, Montoya M, Laliotou B, Aslanoglou E, Kouvatsis V, Entwisle C, Miller J, Klenerman P, Hadziyannis A, Hadziyannis S, Borrow P, Mavromara P. *Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. **The Journal of General Virology.** 2003;84(Pt 3):545-54.*
27. **Tsitoura E**, Lucas M, Revol-Guyot V, Epstein AL, Manservigi R, Mavromara P. *Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. **The Journal of General Virology.** 2002;83(Pt 3):561-6.*

Review articles – peer reviewed publications

1. Wendelberger B, Jensen TP, Quintana M, Stewart I, Molyneaux PL, Maher TM, Oldham JM, Johnson SR, Fahy WA, Khan F, Saini G, Abdulqawi R, Allen R, Baldi BG, Chaudhuri N, Corte TJ, Cottin V, Funke-Chambour M, Glaspole I, Holland AE, Johansson KA, Khor YH, Kreuter M, Kulkarni T, Molina-Molina M, Martinez FJ, Montesi SB, Nathan SD, Piccari L, Rajan S, Rivera-Ortega P, Ryerson CJ, Sakamoto K, Wain LV, Wells AU, Adams W, Kawano-Dourado L, Jenkins RG, Lewis RJ; **REMAP-ILD Consortium Investigators.** *A statistical Model for Lung Function Trajectory and Mortality in Patients with Fibrotic Interstitial Lung Disease. **Am J Respir Crit Care Med.** 2026 Apr 7:aamag103.*
2. Kawano-Dourado L, Kulkarni T, Ryerson CJ, Rivera-Ortega P, Baldi BG, Chaudhuri N, Funke-Chambour M, Hoffmann-Vold AM, Johansson KA, Khor YH, Montesi SB, Piccari L, Prosch H, Molina-Molina M, Sellares Torres J, Bauer-Ventura I, Rajan S, Jacob J, Richards D, Spencer LG, Wendelberger B, Jensen T, Quintana M, Kreuter M, Gordon AC, Martinez FJ, Kaminski N, Cornelius V, Lewis R, Adams W, Jenkins G; **REMAP-ILD consortium.** *Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases. **Thorax.** 2024 Jul 16;79(8):788-795.*
3. Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson CJ, Jenkins G; **REMAP-ILD Consortium.** *Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. **BMJ Open Respir Res.** 2024 Feb 27;11(1):e002163.*
4. Ntatsoulis K*, Karampitsakos T*, **Tsitoura E***, Stylianaki EA, Matralis AN, Tzouvelekis A, Antoniou KM, Aidinis V. (*equal contribution). *Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. **Front Immunol.** 2021 Oct 4;12:687397.*
5. Antoniou KM*, **Tsitoura E***, Vasarmidi E, Symvoulakis EK, Aidinis V, Tzilas V, Tzouvelekis A, Bouros D. (*equal contribution). *Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. **Curr Opin Pharmacol.** 2021 Apr;57:71-80.*
6. Funke-Chambour M, Albera C, Bendstrup E, Costabel U, Grutters JC, Harari S, Johansson KA, Kreuter M, Strambu I, Vancheri C, Varone F, Vitulo P, Wuyts WA, Martinez F, Raghu G; **Erice ILD Working Group.** *Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. **Eur Respir J.** 2021 Apr 29;57(4):2004219*

7. Vasarmidi E, **Tsitoura E**, Spandidos DA, Tzanakis N, Antoniou KM. *Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)*. **Exp Ther Med**. 2020;Sep;20(3):2557-2560.
8. Bolaki M, **Tsitoura E**, Spandidos D, Symvoulakis E and Antoniou KM. *Respiratory diseases in the era of Covid-19: Pearls and pitfalls*. **Exp Ther Med**. 2020;20(2):691-693.
9. **Tsitoura E**, Bibaki E, Bolaki M, Vasarmidi E, Trachalaki A, Symvoulakis E, Spandidos D and Antoniou KM. *Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver*. **Exp Ther Med**. 2020;20(1):147-150.
10. Antoniou KM, Karagiannis K, **Tsitoura E**, Bibaki E, Lasithiotaki I, Proklou A, Spandidos DA, Tzanakis N. *Clinical applications of mesenchymal stem cells in chronic lung diseases*. **Biomed Rep**. 2018 Apr;8(4):314-318
11. Johansson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; **Erice ILD Working Group**. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? **Lancet Respir Med** 2017 Jul;5(7):591-598.
12. Antoniou KM, Karagiannis K, **Tsitoura E**, Tzanakis N. *Mesenchymal stem cell treatment for IPF-time for phase 2 trials?* **Lancet Respir Med** 2017, Jun;5(6):472-473
13. **Tsitoura E**, Bibaki E, Vasarmidi E, Antoniou KM. *Hot topics in IPF Pathogenesis: ERS and ATS highlights* **Pneumon**. 2016;2(28).
14. Antoniou KM, Tomassetti S, **Tsitoura E**, Vancheri C. *Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update*. **Curr Opin Pulm Med**. 2015;21(6):626-33.
15. **Tsitoura E**, Lasithiotaki I, Vasarmidi E, Sourvinos G, Antoniou KM. *Lung Cancer and Idiopathic Pulmonary Fibrosis: from epigenetics to drug therapy*. **Pneumon**. 2015;1(28).
16. Margaritopoulos GA, **Tsitoura E**, Tzanakis N, Spandidos DA, Siafakas NM, Sourvinos G, et al. *Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis*. **BioMed research international**. 2013;2013:420497.
17. **Tsitoura E**, Epstein AL. *Constitutive and Inducible Innate Responses in Cells Infected by HSV-1-Derived Amplicon Vectors*. **Open virology journal**. 2010;4:96-102.
18. **Tsitoura E**, Georgopoulou U, Mavromara P. *HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins*. **Current gene therapy**. 2006;6(3):393-8.

Presentations in International Conferences

Oral presentations

1. **Tsitoura E**, Lampiri E, Vasarmidi E, Zevla MD, Bibaki E, Bizymi N, Tzanakis N, Antoniou K. *Increased CD14+ monocytes and OPN+ positive airway macrophages in the BAL are associated with Post-COVID-19 induced altered respiratory function*. **European Respiratory Society Congress 2022, Barcelona, Spain**.
2. **Tsitoura E**, Bibaki E, Vasarmidi E, Kokosi M, Karagiannis K, Trachalaki A, Margaritopoulos GA, Tzanakis N, Wells AU and Antoniou KM. *Let7c is reduced in IPF BAL cells relative to other fibrotic ILDs and is associated with disease progression and survival in fibrotic lung disease*. **17th ERS Lung Science Conference 2019: 'Mechanisms of Acute Exacerbation of Respiratory Disease'**. Estoril, Portugal.
3. **Tsitoura E**, Bibaki E, MD, Koutsopoulos A, Lagoudaki E, Karagianni K, Vasarmidi E, Trachalaki A, Tzanakis N, Crestani B, **Antoniou K**. Upregulation of Retinoic Acid-Related Orphan Receptor-alpha (RORa) in IPF; a promising therapeutic target; **WASOG, 2018, Hersonisos, Greece**; OP-06.

4. Vasarmidi E, **Tsitoura E**, Sarantoulaki S, Koutoulaki C, Charalambous I, Margaritopoulos G, et al. *Investigation of mitochondria homeostasis and mitophagy in bronchoalveolar lavage fluid (BALF) cells in pulmonary fibrosis*. **European Respiratory Society Congress 2015, Amsterdam, Netherlands** Eur Respir J. 2015;46(suppl 59).
5. Lasithiotaki I, **Tsitoura E**, Koutsopoulos A, Lagoudaki E, Spandidos D, Siafakas N, Sourvinos G, Antoniou K. *Overexpression of miR-21 in non-small cell lung cancer, positive for Merkel cell polyoma virus (MCPyV)*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2015**
6. **Tsitoura E**, Bibaki E, Koutsopoulos A, Koutoulaki H, Lagoudaki E, Charalambous E, et al. *Retinoic acid-related orphan receptor alpha (ROR alpha) expression in pulmonary fibrosis*. **Int J Mol Med. 2015, Athens, Greece**;36:S103-S.
7. **Tsitoura E**, Wells AU, Karagiannis K, Lasithiotaki I, Sarantoulaki S, Sato H, et al. Decreased MicroRNA29a expression in Idiopathic Pulmonary Fibrosis (IPF) is associated with Collagen type, 1a1 expression and eosinophilia in Bronchoalveolar Lavage Fluid (BALF). **Int J Mol Med. 2014 Athens, Greece**;34:S105-S.
8. **Tsitoura E**, Antoniou K, Psaraki A, Lasithiotaki I, Spandidos D, Sourvinos G, et al. Regulation of microRNAs in response to herpes simplex virus type-1 (HSV-1) infection in idiopathic pulmonary fibrosis. **European Respiratory Society Congress 2014, Munich, Germany**, Eur Respir J. 2014;42(Suppl 57).
9. Antoniou K, **Tsitoura E**, Psaraki A, Lasithiotaki I, Spandidos D, Sourvinos G, et al., et al. *Regulation Of MicroRNAs Involved In Idiopathic Pulmonary Fibrosis (IPF) And The Role Of Herpes Simplex Virus Type-1 (HSV-1) Infection In MicroRNA Expression In Bronchoalveolar Lavage Fluid (BALF) Cells*. **American Thoracic Society International Conference, San Diego, California**, Abstracts: American Thoracic Society; 2014. p. A3922-A.

Poster presentations in International Conferences

1. Eleni M. Ladopoulou*, Espen Schallmayer*, **Eliza Tsitoura***, Ioanna Kalogeropoulou, Stefanos Smyrniotis, Marilena Lourou, Carina Fischer, Elli-Anna Stylianaki, Anastasios V. Koutsopoulos, Michalis Papadourakis, Antreas Afantitis, Skarlatos G. Dedos, Henrik Oster, Vassilis Aidinis, Katerina M. Antoniou, Daniel Merk, and Alexios N. Matralis *Selective RORα Inverse Agonism: A Novel Therapeutic Target in Idiopathic Pulmonary Fibrosis* **European Respiratory Society Congress, Barcelona, Spain 2026**. Accepted
2. Eirini Vasarmidi, Athina Trachalaki, Ioanna Argyriou, Rianne de Vries, Nikoleta Bizymi, Marilena Lourou, Konstantina Symvoulaki, Christian Hesslinger, Daniel Peter, Lutz Wollin, **Eliza Tsitoura**, Katerina M. Antoniou. The role of electronic nose (e-nose) technology in ILD diagnosis and BAL cell discrimination. **WASOG 2026 Porto, Portugal**. Accepted
3. **Eliza Tsitoura**, Eirini Vasarmidi, Ioanna Argyriou, Matthew Kerr, Liam Grimmett, Jessica Herbert, Owen Birch, Tilly Woodland, Huw Davies, Athina Trachalaki, Marilena Lourou, Lutz Wollin, Katerina M. Antoniou. VOC breath signatures with diagnostic, subtype stratification, and prognostic potential in interstitial lung diseases **WASOG 2026 Porto, Portugal**. Accepted
4. **Tsitoura E**, Jannis B. Spintge, Eirini Vasarmidi, Thorsten Beckmann, Benedikt Reiz, Henning Dickten, Thomas Ulas, Ioanna Argyriou, Marilena Lourou, Julia Soellner, Lutz Wollin, Christian Hesslinger, Christian T. Wohnhaas, Patrick Baum, Katerina Antoniou. *Single-cell analysis identifies rare CCLHi monocyte-derived alveolar macrophages as a potential ILD biomarker*. **European Respiratory Society Congress, Amsterdam, Netherlands 2025**, European Respiratory Journal. 2025;66(suppl 69).
5. E. Vasarmidi, **E. Tsitoura**, M. Lourou, I. Argyriou, E. Bibaki, K. Karagiannis, A. Zouraraki, N. Tzanakis, S. Schiza, K. M. Antoniou. Clinical characteristics, BALF composition and Follow-up Data of Patients with UnclassifiableILD; Results from a single-center study. **European Respiratory Society Congress, Amsterdam, Netherlands 2025**, European Respiratory Journal. 2025;66(suppl 69).
6. Liva G., **Tsitoura E.**, Bizymi N, Lourou M., Argyriou I., Andreatidi K., Matthaïou A., Prokopakis E., Tzanakis N., Karatzanis A., Koutsopoulos A., Antoniou KM. *Effect of anti-IL5 treatment on upper airway basement membrane thickness in patients with CRSwNP and mild asthma – preliminary results*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2025**, European Respiratory Journal. 2025;66(suppl 69).
7. G. Liva, S. Viziriannaki, **E. Tsitoura**, M. Lourou, N. Bizymi, I. Argyriou, E. Prokopakis, A. Karatzanis, N. Tzanakis KM. Antoniou. *Role of epithelial barrier integrity in Biologic treatment response of severe asthmatics with/out chronic*

8. Antoniou KM, Argyriou I, Vasarmidi E, Lourou M, de Vries R, Hesslinger C, Peter D, Wollin L, **Tsitoura E**. *Interim study analysis supports experimental use of exhaled breath analysis for ILD diagnosis. American Thoracic Society International Conference 2025 San Fransisco, California*, American Journal of Respiratory and Critical Care Medicine. 2025 May;211(Abstracts):A4608.
9. K Antoniou, E Vasarmidi, A Galaras, M Lourou, I Argyriou, N Bizymi, D Zevla, C Skiadas, P Hatzis, I Lambiri, V Aidinis, N Tzanakis, AU Wells, **E Tsitoura**. *Bronchoalveolar Lavage Fluid Cell Gene Expression Signatures Are Suggestive of Prolonged Innate Immune Activation in Patients With Persistent Post-covid-19 ILD. American Thoracic Society International Conference 2025 San Fransisco, California*. American Journal of Respiratory and Critical Care Medicine. 2025 May;211(Abstracts):A4218.
10. Vasarmidi E, **Tsitoura E**, Lourou M, Argyriou I, Bibaki E, Antoniou KM. *Increased lung monocyte infiltration in Fibrotic Interstitial Lung Diseases (P193) 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF) 2024*.
11. Vasarmidi E, Lourou M, Argyriou I, Galaras A, Lambiri I, Skiadas C, Hatzis P, Aidinis V, Tzanakis N, **Tsitoura E***, Antoniou KM*. **equal contribution, Immune cell imbalance linked to persistent damage after COVID-19,(P196) 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF) 2024*.
12. Vasarmidi E, Argyriou I, Galaras A, Lourou M, Lambiri I, Skiadas C, Bibaki E, Bizymi N, Matthaïou AM, Hatzis P, Tzanakis N, **Tsitoura E**, Antoniou KM. *Distinct airway immune cell constitution in persistent post COVID-19 ILD. European Respiratory Society Congress, Vienna, Austria, 2024*, European Respiratory Journal. 2024;66(suppl 68).
13. Vasarmidi E, **Tsitoura E**, Lourou M, Argyriou I, Galanakis N, Bibaki E, Antoniou KM. *Increased lung monocyte infiltration in Fibrotic Interstitial Lung Diseases. European Respiratory Society Congress, Vienna, Austria, 2024*, European Respiratory Journal. 2024;66(suppl 68).
14. **Tsitoura E**, Lampiri E, Mastrodemou S, Zevla MD, Bibaki E, Bizymi N, Tzanakis N, Antoniou KM. *Increased CD14⁺ monocytes and OPN⁺ airway macrophages in the BAL are associated with Post-COVID-19 induced altered respiratory function. European Respiratory Society Congress, Barcelona, Spain,2022*, European Respiratory Journal. 2022;60(suppl 66).
15. Zevla MD, **Tsitoura E**, Crestani B, Antoniou K. *Inhibitory role of retinoic acid-related orphan receptor alpha RORa in human lung fibroblast activation. European Respiratory Society Congress, Barcelona, Spain,2022*,European Respiratory Journal. 2022;60(suppl 66).
16. Antoniou KM, **Tsitoura E**, Trachalaki A, Vasarmidi E, Margaritopoulos G. Boboki A, Bibaki E, Stamataki E, Meletis G, Tzanakis N. *Long-Term (7 years) experience of Nintedanib in IPF patients in Crete: A real life data study. Thoracic Society International Conference 2020, Virtual Event*, American Journal of Respiratory and Critical Care Medicine 2020;201:A2202
17. **Tsitoura E**, Trachalaki A, Mastrodimou S, Vasarmidi E, Bibaki E, Tzanakis N, Antoniou KM. *Increased NLRP3 and AIM2 activation in IPF alveolar macrophages is associated with mtROS. Thoracic Society International Conference 2020, Virtual Event*, American Journal of Respiratory and Critical Care Medicine 2020;201:A2246
18. Trachalaki A, **Tsitoura E**, Invernizzi R, Mastrodimou S, Vasarmidi E, Byrne A, Maher M T, Antoniou K, Molyneaux L P. *Inflammasome activation in airway macrophages and the lung microbiome in IPF. European Respiratory Society Congress, Barcelona, Spain,2019*, European Respiratory Journal. 2019;54(suppl 63).
19. Vasarmidi E, Bibaki E, Koutoulaki C, Mastrodemou S, Trachalaki A, Tzanakis N, **Tsitoura E** and Antoniou KM. *Evaluation of CD163 expression on alveolar macrophages from BAL of patients with Fibrotic Lung Diseases. European Respiratory Society Congress, Barcelona, Spain,2019*, European Respiratory Journal. 2019;54(suppl 63).

20. Trachalaki A, **Tsitoura E**, Vasarmidi E, Bibaki E, Tzanakis N, Antoniou K. LSC-2019-*Inflammasomes' activation in alveolar macrophages and peripheral blood mononuclear cells in fibrotic Interstitial Lung Diseases*. **European Respiratory Society Congress, Barcelona, Spain, 2019**, European Respiratory Journal. 2019;54(suppl 63).
21. Bibaki E, Vasarmidi E, Koutoulaki C, Mastrodemou S, Trachalaki A, Tzanakis N, **Tsitoura E** and Antoniou KM. *CD163 positive alveolar macrophages from bronchoalveolar lavage in idiopathic pulmonary fibrosis and lung cancer*. **European Respiratory Society Congress, Barcelona, Spain, 2019**, European Respiratory Journal. 2019;54(suppl 63).
22. **Tsitoura E**, Bibaki E, Vasarmidi E, Koutoulaki C, Margaritopoulos G, Karagiannis K, and Antoniou KM *AKT1/AKT2 mRNA Balance Is Significantly Different In IPF BAL Cells Compared To Other Fibrotic ILDs*. **Lung Science Conference 2018, Estoril, Portugal**, European Respiratory Journal. 2018;52(suppl 62).LSC-1182.
23. **Tsitoura E**, Bibaki E, Vasarmidi E, Trachalaki A, Koutoulaki C, Margaritopoulos GA, and Antoniou KM *Let7c and AKT1/AKT2 mRNA balance is different In IPF BAL cells compared to other fibrotic ILDs*. **European Respiratory Society Congress, Paris, France, 2018**, European Respiratory Journal. 2018;52(suppl 62).
24. **Tsitoura E**, Bibaki E, Koutsopoulos A, Lagoudaki E, Karagianni K, Tzanakis N, and Antoniou KM *Upregulation of Retinoic Acid-Related Orphan Receptor-alpha (RORa) in IPF; a promising therapeutic target*. **European Respiratory Society Congress, Paris, France, 2018**, European Respiratory Journal. 2018;52(suppl 62).
25. Trachalaki A, **Tsitoura E**, Vasarmidi E, Bibaki E, Papastratigakis G, Margaritopoulos G, and Antoniou KM *Development of assays to evaluate inflammasomes' activity in the peripheral blood and in alveolar macrophages in fibrotic lung diseases*. **European Respiratory Society Congress, Paris, France, 2018**, European Respiratory Journal. 2018;52(suppl 62).
26. Michelakis S, Bouloukaki I, **Tsitoura E**, Mermigkis C, Antoniou KM, Tzanakis N, et al. *Investigation of KL-6, ET-1 and S100A9 levels in idiopathic pulmonary fibrosis (IPF) patients with Obstructive sleep apnea (OSA)*. **Congress of the European Sleep Research Society, Basel, Switzerland, 2018**, J Sleep Res. 2018;27.
27. Trachalaki A, **Tsitoura E**, Vasarmidi E, Bibaki E, Papastratigakis G, Margaritopoulos G, Tzanakis N, **Antoniou K**. Development of assays for the evaluation of inflammasomes' activity in alveolar macrophages in fibrotic lung diseases; **WASOG, 2018, Hersonisos, Greece**; OP-07.
28. Bibaki E, **Tsitoura E**, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Tzanakis N, **Antoniou K**. MiR-185/miR-29a similarly expressed in IPF and CA BALF-cells show disease specific DNMT1 and COL1A1 patterns; **WASOG, 2018, Hersonisos, Greece**; OP-08.
29. Vasarmidi E, **Tsitoura E**, Koutoulaki C, Margaritopoulos G, Trachalaki A, Tzanakis N, **Antoniou K**. Alveolar macrophages show elevated oxidized mitochondria levels in IPF. Possible link with mitophagy and autophagy; **WASOG, 2018, Hersonisos, Greece**; SOP-11.
30. Kokosi M, Kouranos V, Trachalaki A, Stock C, Donovan J, **Tsitoura E**, Renzoni E, Wells AU, **Antoniou K**. Serum KL-6 in Fibrosing Interstitial Lung Diseases ; **WASOG, 2018, Hersonisos, Greece**; SOP-12.
31. Bibaki E, **Tsitoura E**, Vasarmidi E, Margaritopoulos G, Trachalaki A, Koutoulaki C, et al. *miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns*. **Mol Med Rep. Athens, Greece 2018**;17(5):7105-12.
32. Chatziantoniou A, Apostolou E, **Tsitoura E**, Synolaki E, Markaki L, Gialamas I, et al. *Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline*. **European Respiratory Society Congress, Milan, Italy, 2017**, European Respiratory Journal. 2017;50(suppl 61).
33. Bibaki E, Georgopoulou T, Koutoulaki C, **Tsitoura E**, Vasarmidi E, Tzanakis N, et al. *The expression of miR185, miR29a and their targets in IPF and lung cancer (LC). A BALF study*. **European Respiratory Society Congress, Milan, Italy, 2017**, European Respiratory Journal. 2017;50(suppl 61).

34. **Tsitoura E**, Wells AU, Koutoulaki C, Karagiannis K, Lasithiotaki I, Vasarmidi E, et al. *MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages*. **European Respiratory Society Congress, London, UK, 2016**, European Respiratory Journal. 2016;48(suppl 60).
35. Proklou A, Pitsidianakis G, **Tsitoura E**, Koutoulaki C, Hatziantoniou A, Moraitaki D, et al. *Triggering receptor expressed on myeloid cells (TREM1): A novel biomarker in the investigation of non-CF bronchiectasis? Preliminary results*. **European Respiratory Society Congress, London, UK, 2016**, European Respiratory Journal. 2016;48(suppl 60).
36. Michelakis S, **Tsitoura E**, Bouloukaki I, Moniaki V, Malliaraki N, Papadogiannis G, et al. *Investigation of KL-6 levels in patients with IPF- OSA overlap syndrome: Preliminary results*. **European Respiratory Society Congress, London, UK, 2016**, European Respiratory Journal. 2016;48(suppl 60).
37. Vasarmidi E, **Tsitoura E**, Margaritopoulos G, Koutoulaki C, Michelakis S, Charalambous I, Tzanakis N, et al. *IPF BALF Cells Show Reduced Expression of PINK1 Coupled to Elevated Oxidized Mitochondria Levels*. **American Thoracic Society International Conference 2016, San Fransisco, California**, American Journal of Respiratory and Critical Care Medicine **2016**;193:A4025
38. Vasarmidi E, **Tsitoura E**, Sarantoulaki S, Koutoulaki C, Charalambous I, Margaritopoulos G, Siafakas N, Antoniou K. *Investigation of mitochondria homeostasis and mitophagy in bronchoalveolar lavage fluid (BALF) cells in pulmonary fibrosis*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2015**, Eur Respir J. 2015;46(suppl 59).OA3513
39. Lasithiotaki I, **Tsitoura E**, Koutsopoulos A, Lagoudaki E, Spandidos D, Siafakas N, Sourvinos G, Antoniou K. *Overexpression of miR-21 in non-small cell lung cancer, positive for Merkel cell polyoma virus (MCPyV)*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2015**, Eur Respir J. 2015;46(suppl 59).
40. Samara KD, Lasithiotaki I, **Tsitoura E**, Giannarakis I, Psaraki A, Bibaki E, Lambiri I, Siafakas N, Antoniou KM. *Lung cancer immune cells exhibit inhibited inflammasome response*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2015**, Eur Respir J. 2015;46(suppl 59).
41. Bibaki E, **Tsitoura E**, Koutoulaki C, Vasarmidi E, Stamataki E, Moraitaki D, Tzanakis N, Antoniou K. *Expression of miR-185 targets DNA methyltransferase 1 and Cyclin D2 in IPF and lung cancer in BALF cells: Preliminary results*. **European Respiratory Society Congress, Amsterdam, Netherlands, 2015**, Eur Respir J. 2015;46(suppl 59).
42. **Tsitoura E**, Koutsopoulos A, Lagoudaki E, Charalambous E, Sourvinos G, Siafakas N, Antoniou KM. *Retinoic Acid-related Orphan receptor-a (RORa) expression and subcellular localization in lung fibroblasts and pneumocytes is associated with fibroblast activation and fibrosis in fibrotic lung tissue specimens*. **American Thoracic Society International Conference 2015 Denver, Colorado**, American Journal of Respiratory and Critical Care Medicine **2015**;191:A4934.
43. Bibaki E, Koutsopoulos A, **Tsitoura E**, Lagoudaki E, Sarantoulaki S, Lasithiotaki I, Siafakas N, Sourvinos G, Antoniou K. *Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study* **European Respiratory Society Congress, Munich, Germany, 2014**, Eur Respir J. 2014;44(suppl 58):4631
44. Sarantoulaki S, Margaritopoulos G, **Tsitoura E**, Karagiannis K, Bibaki e, Wells AU, Siafakas N, Sourvinos G, Antoniou KM. *Autophagy is not impaired in BALF alveolar macrophages in IPF: preliminary results*. **European Respiratory Society Congress, Munich, Germany, 2014**, Eur Respir J. 2014;44(suppl 58):P779
45. **Tsitoura E**, Wells AU, Karagiannis K, Lasithiotaki I, Sarantoulaki S, Sato H, Spandidos DA, Siafakas NM, Sourvinos G, Antoniou KM. *Decreased MicroRNA29a expression in Idiopathic Pulmonary Fibrosis (IPF) is associated with Collagen type, 1a1 expression and eosinophilia in Bronchoalveolar Lavage Fluid (BALF)*. **Int J Mol Med. Athens, Greece 2014**;34:S105-S.
46. Antoniou KM, Tsitoura E, Sarantoulaki S, Giannarakis I, Psaraki A, Karagiannis K, Sato H, Wells, AU, Sourvinos G, Siafakas NM. *Regulation Of MicroRNAs Involved In Idiopathic Pulmonary Fibrosis (IPF) And The Role Of Herpes Simplex Virus Type-1 (HSV-1) Infection In MicroRNA Expression In Bronchoalveolar Lavage Fluid (BALF) Cells*. **American Thoracic Society International Conference 2014 San Diego, California**, American Journal of Respiratory and Critical Care Medicine **2014**;189:A3922.

47. **Tsitoura E**, Kokkinaki C, Spandidos DA, Antoniou KM, Sourvinos G. *HSV-1 controls cellular microRNAs involved in innate immune responses*. **Int J Mol Med. Athens, Greece 2013;32:S70-S.**
48. **Tsitoura E**, Antoniou KM, Psaraki A, Lasithiotaki I, Kokkinaki C, Spandidos DA, Siafakas NM, Sourvinos G. LSC 2013 abstract-Regulation of microRNAs in response to herpes simplex virus type-1 (HSV-1) infection in idiopathic pulmonary fibrosis (IPF): Preliminary results. **Lung Science Conference. Estoril, Portugal 2013, Eur Respir J. 2013;42(suppl 57):PP142**
49. **E. Tsitoura**, C. Kokkinaki, D.A. Spandidos, K.M. Antoniou, G. Sourvinos. *Regulation of cellular microRNAs involved in innate immune responses by HSV-1*. **5th European Congress of Virology, September 11-14, 2013, Lyon, France.**
50. Kazazi D, **E. Tsitoura**, N. Vassilaki, E. Aslanoglou, M. Kochlios, S. Khalili, D. Oz-Arslan, F. Kreppel, S. Kochanek, G. Jennings, F. Cosset, A. Epstein, T. Dalianis, A. Williamson, B. Bellier, A. Six, T. Brocker, T. Ivacevic, V. Benes, D. Klatzmann and P. Mavromara. *Gene expression profiling of dendritic cells upon in vivo exposure to candidate vaccine vectors*. **5th International Greek Biotechnology Forum, July, 2009, Athens, Greece.**
51. Oz-Arslan, D., **Tsitoura, E.**, Kazazi, D., Foka, P. and Mavromara, P. *Characterisation of dendritic cell related mRNA expression profile elicited by HSV-1 and HSV-1-based amplicon vectors*. **XIV, International Congress of Virology, 11-15 August, 2008, Istanbul, Turkey.**
52. Khalili, S., Oz-Arslan, D., Kazazi, D., Ivacevic, T., **Tsitoura, E.**, Kreppel, F., Kochanek, S., Jennings, G., Bellier, B., Brocker, T., Benes, V., Klatzmann, D. and Mavromara, P. *Gene expression profiling of dendritic cells upon in vivo exposure to recombinant viral vaccine vectors and virus like particles (VLPs)*. **Challenges of Global Vaccine Development, Keystone Symposia, 8-13, October, 2007, Cape Town, South Africa.**
53. **Tsitoura E.**, and Epstein A. *Effect of HSV-1 infection on the expression of TLRs in primary human fibroblasts in the absence of viral gene expression using HSV-1-based amplicon vectors*. **31th International Herpesvirus Workshop. Seattle, Washington USA July 22-28, 2006.**
54. **Tsitoura E.**, Thomas J. and Epstein A. *Studies on the involvement of the innate antiviral response on the silencing of transgenic expression driven by HSV-1-based amplicon vectors*. **13th Annual congress of the European Society of Gene Therapy. Prague, Czech Republic. October 2005.**
55. Kouvatsis V., Argnani R., **Tsitoura E.**, Mavromara P. and Manservigi R. *Recombinant Herpes Simplex Virus type 1 expressing and incorporating hepatitis C virus chimeric glycoproteins*. **30th International Herpesvirus Workshop. Turku, Finland July 2005.**
56. **Tsitoura E**, Thomas J. and Epstein A. *Induction of innate immune responses in cells infected with HSV-1-based amplicon vectors*. **30th International Herpesvirus Workshop. Turku, Finland July 2005.**
57. **Tsitoura E.**, Boleti H., Disson O., Hibner U., Mavromara P., and Epstein A. *Herpes simplex virus type 1 (HSV-1)-based amplicon vectors expressing the structural region of the hepatitis C virus (HCV) induce the assembly of HCV virus-like particles*. **28th International Herpesvirus Workshop. Madison, Wisconsin, USA, July 2003.**
58. **E. Tsitoura**, M. Dietsch, E. Aslanoglou, P. Mavromara, and A. Epstein. *Characterisation of the Hepatitis C Virus structural proteins expressed by herpes simplex virus 1 amplicon vectors*. **8th International Meeting on Hepatitis C Virus and related Viruses, Molecular Virology and Pathogenesis. Paris, France. September 2001.**
59. M. Dietsch, **E. Tsitoura**, E. Aslanoglou, C. Entwisle, J. Miller, R. Maldonado-Lopez, and P. Mavromara. *Characterisation of HCV envelope glycoproteins produced by recombinant Herpes Simplex Viruses*. **7th International Meeting on Hepatitis C Virus and related Viruses, Molecular Virology and Pathogenesis. Queensland, Australia. December 2000.**